Loading
A phase 1 trial of MT-304 run by Myeloid Therapeutics, now recruiting.
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors is a phase 1 interventional study registered as NCT07334119 by Myeloid Therapeutics, with 60 participants planned, started 2025-11-25, primary completion expected 2027-01-31. Conditions recorded: HER2-Expressing Solid Tumors. Interventions recorded: MT-304, MT-304 + Nivolumab.
Shares CREATE Medicines and the tag pipeline.
Shares CREATE Medicines and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/